INTRODUCTION
The biological actions of the insulin-like growth factors, IGF-I and IGF-II, are mediated via interaction with IGF receptors (Van Wyk et al., 1985; Conover et al., 1987; Hari et al., 1987) , and to a lesser extent, with insulin receptors (King et al., 1980) . Two major forms of IGF receptors have been reported. The type I IGF receptor, though distinct from the insulin receptor, contains many similar amino acid sequences (Ullrich et al., 1986) , and is composed ofsimilarly sized Mr-135 000 (a) and Mr-95 000 () subunits linked by disulphide bonds into a heterotetrameric complex (Massague & Czech, 1982; Kull et al., 1983) . The type II IGF receptor is a monomer (Mr 260000) (Massague & Czech, 1982) closely resembling or identical with the mannose 6-phosphate receptor . The type I receptor has a higher affinity for IGF-I than for IGF-II and a low affinity for insulin; the type II receptor has a higher affinity for IGF-II than for IGF-I and no affinity for insulin. Both IGFs cross-react to a small degree with the insulin receptor (Massague & Czech, 1982) .
However, we (Jonas et al., 1986 (Jonas et al., , 1989 and others (Hintz et al., 1984; Tollefson et al., 1987) have also described another type of receptor in human placenta which binds IGFs and insulin with high affinity. These atypical insulin receptors, which co-purify with insulin receptors during insulin affinity chromatography (Jonas et al., 1986 (Jonas et al., , 1989 Tollefson et al., 1987) have the same subunit structure and immunological properties as insulin receptors and do not cross-react with a monoclonal antibody to the type I IGF receptor (aIR-3) (Jonas et al., 1986 (Jonas et al., , 1989 . They differ from classical insulin receptors in their unusually high affinity for multiplicationstimulating activity (MSA, the rat homologue of IGF-II) and IGF-I, account for 10-20 % of the total insulinreceptor population, and can be detected by precipitation with a polyclonal insulin-receptor antibody (B-10) after labelling with '251-MSA (Jonas et al., 1986 (Jonas et al., , 1989 .
The cells of the IM-9 human lymphoid-derived line also contain an unusual population of IGF-II-binding sites (Hintz et al., 1984) , whose immunological and hormone binding characteristics (Misra et al., 1986) resemble those of the atypical insulin receptors of human placenta. However, the studies by Misra et al. (1986) were conducted on whole IM-9 cells and particulate membranes, whereas our placental studies were performed on solubilized receptors separated from type I IGF receptors by B-10 precipitation or insulin affinity chromatography (Jonas et al., 1986 (Jonas et al., , 1989 . Furthermore, MSA bound with higher affinity (about 10-fold) to the solubilized atypical receptors from placenta than did IGF-II to the surface of intact IM-9 cells. Thus it is possible that the unusual IGF-II-binding properties of IM-9 cells might not reflect the presence of atypical insulin receptors: they may, instead, represent membrane interactions between type I IGF receptors, insulin receptors and neighbouring non-receptor proteins.
Therefore, to determine whether the IGF-II/MSAbinding properties of IM-9 cells were maintained after membrane disruption and removal of type I IGF receptors, we examined binding of insulin, Abbreviations used: IGF, insulin-like growth factor; MSA, multiplication-stimulating activity; PMSF, phenylmethanesulphonyl fluoride; CDI-agarose, l,1'-carbonyldi-imidazole-activated agarose; PEG, poly(ethylene glycol) 6000.
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IM-9 receptors on whole cells, particulate membranes and solubilized membranes precipitated with B-10 or purified by insulin affinity chromatography. To compare accurately the MSA-binding properties of IM-9 cells with those of the placental atypical insulin receptors, affinity-purified IM-9 receptors were assayed under the same conditions as for their placental counterparts.
MATERIALS AND METHODS Materials
The reagents used in this study, including unlabelled and l25l-labelled insulin, MSA and IGF-I, and antisera B-10 and aIR-3, have been described previously (Jonas et al., 1989) . IM-9 cells, membrane preparations and affinity-purified receptors IM-9 cells, an established human lymphoid-derived cell line obtained from Dr. R. Hintz (Stanford, CA, U.S.A.), were grown in RPMI-1640 medium (Flow Laboratories, Sydney, Australia) supplemented with 2 g of NaHCO3/l, 2 mM-L-glutamine and 10 % (v/v) fetalcalf serum (Flow Laboratories, Australia) . Cells in lateexponential to early stationary phase were harvested by centrifugation, then washed in phosphate-buffered saline (8.0 g ofNaCl/l, 1.15 g of Na2HPO4/l, 0.2 g of KH2PO4/1 and 0.2 g of KCl/l, pH 7.4) or 0.15 M-NaCl.
Membranes were prepared from washed IM-9 cells [(1-3.5) x 109] by using the homogenization and centrifugation procedures described by Misra et al. (1986) . The 20000 g pellet was washed with lymphocyte-binding buffer (O.1 M-Hepes, 0. 12 M-NaCl, 1.2 mM-MgSO4, 5 mMKCl, 15 mM-sodium acetate, 1 mM-EDTA and 10 mmglucose, pH 7.5) containing no added BSA, then resuspended to a final volume equivalent to 175 x 106 cells/ml, or 1 mg of membrane protein/ml. Portions of the resuspended membranes were solubilized with an additional 0.25 vol. of Triton X-100 (50 g/l) containing Trasylol (5000 Kallikrein units/ml), 10 mM-phenylmethanesulphonyl fluoride (PMSF) and bacitracin (2500 units/ml) for 1 h at 4 "C, then centrifuged at 100000 g for 1.5 h at 4 "C. Particulate and solubilized membranes were stored at -70 "C until assay.
To purify the insulin receptors, washed IM-9 cells (810 x 106) were solubilized in 12 ml of 0.1 M-sodium phosphate, pH 7.5, containing Triton X-100 (10 g/l), Trasylol (1000 Kallikrein units/ml), PMSF (2 mM) and bacitracin (500 units/ml) for 2 h at 4 "C. After centrifugation at 100000 g (1.5 h at 4 "C), the supernatant was subjected to sequential affinity chromatography on wheat-germ-lectin-Sepharose 6MB and insulin-i,1'-carbonyldi-imidazole-activated agarose (CDI-agarose) under the conditions described by Newman & Harrison (1985) . Purified receptors were eluted from the insulin-CDI-agarose column with 0.05 M-sodium acetate, pH 5.0, containing 1 M-NaCl, Triton X-100 (1 g/l) and 0.1 mM-PMSF, and neutralized with 0.25 vol. of 1 MTris/HCl, pH 7.4. Binding assays Cells (4 x 106) were incubated with 15000-20000 c.p.m. of`25I-insulin, 125I-MSA or 125I-IGF-I and increasing concentrations of unlabelled insulin, MSA and IGF-I in a total of 0.2 ml of lymphocytebinding buffer, pH 8.0, containing BSA (10 g/1) and bacitracin (45 units/ml). Incubations were performed in 12 mm x 75 mm plastic tubes in a shaking water bath for 90-120 min at 15 'C. To separate cells from unbound hormones, the cells were mixed with 0.5 ml of ice-cold buffer containing BSA (10 g/l), centrifuged for 5 min at 4000 g, then washed and centrifuged again. In some experiments, cells were assayed after preincubation for 30 min at 15 'C with saturating concentrations of aIR-3 [10-fold dilution of serum-free RPMI 1640 conditioned medium from the aIR-3 hybridoma clone, concentrated 20-fold against an Amicon PM-30 (Mr 30000) membrane]. Unbound aIR-3 was removed by washing with lymphocyte-binding buffer, before addition of hormones.
IM-9 membranes (20-40 ,ug of protein) were similarly incubated with '251-labelled and unlabelled hormones in a final assay volume of 0.2 ml. To separate membranes from unbound hormones, 1.0 ml of ice-cold buffer containing BSA (10 g/l) was added to each tube, and the membranes were centrifuged for 20 min at 4000 g.
Neutralized eluates or 'flow-through' fractions from the insulin-CDI-agarose column or solubilized membranes (40 ,g of protein) in neutralized eluent buffer containing 1-2 g of Triton X-100/l (0.1 ml) were incubated with 125I-labelled and unlabelled hormones (0.1 ml; in 0.1 M-sodium phosphate buffer, pH 7.5, containing 10 g of BSA/l) for 18-24 h at 4 'C. Receptor-bound hormone was precipitated by poly(ethylene glycol) 6000 (PEG) or immunoprecipitated with B-10 IgG (final dilution 14 ,tg/ml) and Staphylococcus aureus as previously described (Jonas et al., 1982) .
Total binding was expressed as a percentage of the total radioactivity added per assay tube. To determine specific binding (B %) of 'l25-insulin, 1251-MSA or 1251. IGF-I to their receptors, the non-specific binding of radioactivity in the presence of unlabelled insulin (5 ,tg) or unlabelled IGF (2 ptl of 0.05 % pure preparation) was subtracted from total binding. The incubations used to determine non-specific binding and specific binding in the absence of unlabelled hormone were performed in quadruplicate. All other incubations were performed in duplicate. Data from the competition-binding studies were analysed by the method of Scatchard (1949) . respectively. Like Misra et al. (1986) , we found that the binding of 125I-insulin and 125I-MSA was displaced by 50 % by low concentrations of unlabelled insulin (14-28 ng/ml and 7-14 ng/ml respectively), but not by aIR-3. Moreover, the relative concentrations of unlabelled insulin, MSA and IGF-I required to displace 50 0 of bound 1251-insulin and 1251-MSA (2:80: > 290 and 1:4.7:29 respectively; mean proportions from five experiments) were very similar to those reported for the classical and atypical insulin receptors of human placenta (Jonas et al., 1989 Binding studies to particulate and solubilized IM-9 membranes The affinity-purifed IM-9 receptors, like their placental counterparts, bound insulin, MSA and IGF-I with much higher affinity than did intact IM-9 cells (Ka = 24 x I09 M-1, 2.7 x 109 M-' and 2.4 x 109 M-1, versus 1.6 x 109 M-1, 0.2 x l09 M-1 and 0.4 x 109 M-1 respectively). To determine whether the higher binding affinities could be ascribed to the different assay conditions, we measured labelled hormone binding to particulate IM-9 membranes (20 ,ug of protein) in lymphocyte binding buffer (15°C for 1.5 h, pH 8) or in 0.1 M-sodium phosphate buffer diluted 1:1 with neutralized eluent buffer (0.2 MTris/HCl/0.04 M-sodium acetate/0.8 M-NaCl) (4°C for 18 h, pH 8). Under the latter conditions of incubation, the binding values for 1251-insulin, 1251-MSA and 1251_ IGF-I were higher (48 00, 21 00 and 200, compared with 31 00, 400 and 3 % respectively; see also Table 1 ), and lower concentrations of unlabelled insulin and MSA were required to displace 50 % of bound 1251-insulin and 1251_MSA (Table 1) .
RESULTS
However, the relative binding displacement patterns for 1251-insulin and 1251-MSA did not change substantially, and were maintained for solubilized membranes precipitated by PEG or by antibody B-10 (Table 1) . When 1251I-IGF-I was substituted for 1251-MSA as tracer, the displacement patterns obtained for solubilized membranes precipitated by antibody B-10 were the same (Table 1) . We also noted that the proportion of MSAbinding sites compared with total insulin-binding sites in solubilized membranes precipitated by antibody B-10 was very similar to that obtained for intact cells ( -30 %/) (Fig. 3) .
extents by unlabelled IGF-I, MSA and insulin, the relative concentrations for different batches of cells ranging from 1:4:70 to 1:2.7:10 ( Fig. la) Binding studies to IM-9 receptors purified by insulin affinity chromatography
The IM-9 receptors purified by insulin affinity chromatography contained a sub-population of IGFbinding sites (identified by '25I-MSA and '25I-IGF-I binding) which closely resembled the placental affinitypurified atypical insulin receptors (Jonas et al., 1986) in that they bound insulin, MSA and IGF-I with high affinity (Figs. 2b and 2c ) and were quantitatively precipitated by the polyclonal insulin-receptor antibody B-10. The type I IGF receptors were largely excluded from the insulin-CDI-agarose column, because the '25I-MSAand '25I-IGF-I-binding sites appearing in the 'flowthrough' fractions (1.4 pmol compared with 12 pmol eluted) were not immunoprecipitated by antibody B-10 and showed the same patterns of hormone displacement (Figs. 2e and 2J ) characteristic of type I IGF receptors (IGF-I > MSA > insulin) (Jonas et al., 1986 Table 1 ), and the binding data were submitted to Scatchard analysis (a and b respectively). The same batches and concentrations of cells and immunoprecipitated memactivity to type I IGF receptors (Jonas et al., 1989) . These differences are best explained by the different proportions of type I IGF receptors and atypical insulinbinding sites in IM-9 cells and human placenta. When solubilized IM-9 cells were affinity-purified on insulin-CDI-agarose, the number of IGF-binding sites eluted from the insulin affinity column (atypical insulinbinding sites) exceeded the number of IGF-binding sites excluded from the column (type I IGF receptors) by about 8-fold. With similarly purified preparations of human placenta, the ratio of IGF-binding sites eluted from the column to those appearing in the 'flow-through' fractions was about 1:2 (Jonas et al., 1986) .
Other studies have shown that insulin is only 1 % as potent as IGF-I in displacing ['251 ]IGF-I from IM-9 cells (Rosenfeld & Hintz, 1980; Rosenfeld et al., 1982; Morgan & Roth, 1986) . However, we found that the relative potency of insulin compared with IGF-I was usually 1/14 to 1/4. These discrepancies suggest that the strains of IM-9 cells used in the above laboratories contained a smaller proportion of atypical insulin-binding sites compared with type I IGF receptors than did the strain used in our laboratory.
The recent immunological studies by Soos & Siddle branes were also analysed for 1251-MSA binding in the presence of increasing concentrations of unlabelled MSA (see Table 1 ), and the binding data were submitted to Scatchard analysis (c and d respectively).
Vol. 266 (1989) have provided strong evidence that IM-9 cells, human placental membranes and Hep G2 cells contain hybrid forms of the insulin and type I IGF receptors, i.e. receptors composed of the a and / subunits of the insulin receptor and the a and , subunits of the type I IGF receptor. These hybrid receptors are distinct from the atypical insulin receptors, because the former receptors are reactive with cIR-3, and bind IGF-I with more affinity than insulin (Soos & Siddle, 1989) . Thus atypical insulin receptors co-exist with classical insulin receptors, type I IGF receptors and insulin/IGF-I receptor hybrids in IM-9 cells and human placental membranes. So far, we have not been able to separate the atypical and classical insulin-binding sites by immunological means or by MSA affinity chromatography (Jonas et al., 1989 ). Thus we do not know, at this stage, whether atypical insulin receptors form hybrids with classical insulin receptors and/or type I IGF receptors.
Because the atypical insulin/IGF-II-binding sites would account for a sizeable proportion of the insulin, IGF-II and IGF-I binding to IM-9 cells, they may mediate specific actions of insulin and IGFs on lymphoblast function and/or metabolism. Further work is required to determine the modes by which the atypical and classical insulin-binding sites may be differentially regulated, and whether they have evolved to subserve cell-specific functions.
